Results 111 to 120 of about 10,402 (207)

Efficacy and safety of non-pegylated liposomal doxorubicin in metastatic breast cancer therapy

, 2017
Breast cancer is the most frequently diagnosed female cancer in Poland (over 17,500 women). Anthracyclines have become one of the most important drugs in breast cancer systemic treatment.
Gierba-Tomczyk, Joanna, Wójcik, Elżbieta, Kufel-Grabowska, Joanna   +2 more
core  

Preclinical studies of pegylated- and non-pegylated liposomal forms of doxorubicin as radiosensitizer on orthotopic high-grade glioma xenografts

, 2015
International audienceFree doxorubicin (DXR) is not currently used to treat brain tumors because (i) the blood-brain barrier limits the drug deposition into the brain (ii) lethal toxic effects occur when combined with radiation therapy.
Sudour, Hélène, Mriouah, Jihane, Bernier-Chastagner, Valérie, Pinel, Sophie, Barberi-Heyob, Muriel, Chastagner, Pascal   +5 more
core   +1 more source

Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial [PDF]

, 2015
Non-pegylated liposomal doxorubicin (NPLD) has demonstrated antitumour activity equivalent to conventional doxorubicin and a significantly lower risk of cardiotoxicity. This phase II trial was performed to evaluate the activity and the safety of NPLD and
Comandone, Alessandro, DE SANCTIS, RITA, Marrari, Andrea, Lutman, Romano Fabio, Giordano, Laura, Bertuzzi, Alexia, Basso, Umberto, Marchetti, Silvia, Santoro, Armando, Colombo, Piergiuseppe   +9 more
core  

Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane

, 2011
Dexrazoxane is an established treatment option in extravasation of the classic anthracyclines such as doxorubicin, epirubicin, and daunorubicin. However, it is not known whether the protection against the devastating tissue injuries extends into ...
Annemette V. Thougaard, Seppo W. Langer, Thougaard, Annemette V, Sehested, Maxwell, Maxwell Sehested, Langer, Seppo W, Peter Buhl Jensen, Jensen, Peter Buhl   +7 more
core   +1 more source

Pegylated Liposomal Doxorubicin Hydrochloride [PDF]

, 2020
openaire   +1 more source

Regulation of in vivo behavior of TAT-modified liposome by associated protein corona and avidity to tumor cells

International Journal of Nanomedicine, 2018
Mohamadreza Amin,1–3 Mahsa Bagheri,3 Mercedeh Mansourian,3 Mahmoud Reza Jaafari,3 Timo LM ten Hagen1 1Laboratory of Experimental Surgical Oncology, Section of Surgical Oncology, Department of Surgery, Erasmus Medical Center, Rotterdam, the ...
Amin M, Bagheri M, Mansourian M, Jaafari MR, ten Hagen TLM   +4 more
doaj  

EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer

Ernest Moles,1– 4 David W Chang,1– 3 Friederike M Mansfeld,1– 3 Alastair Duly,1,2 Kathleen Kimpton,1 Amy Logan,1– 4 Christopher B Howard,5 Kristofer J Thurecht,5,6 Maria Kavallaris1– 4 1Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW ...
Kavallaris M, Duly A, Chang DW, Thurecht KJ, Moles E, Mansfeld FM, Kimpton K, Howard CB, Logan A   +8 more
core  

Pegylated Liposomal Doxorubicin Consolidation Therapy

The Oncologist, 2006
openaire   +2 more sources

Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors. [PDF]

Clin Cancer Res
Xu H, Hu J, Zhang Y, Zhuang A, Zhang Y, Li J, Wu H, Song G, Deng C, Chen H, Chen W, Deng C, Wang A, Feng H, Lu J, Tang Q, Zhu X, Wang J.   +17 more
europepmc   +1 more source

Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both. [PDF]

Oncologist, 2023
Bonaca MP, Moslehi JJ, Ledermann JA, Michelon E, Wei C, Moran M, Monk BJ, Pujade-Lauraine E.   +7 more
europepmc   +1 more source